107 related articles for article (PubMed ID: 12169987)
1. Autoantibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review.
Mozo L; Simó A; Suárez A; Rodrigo L; Gutiérrez C
Eur J Gastroenterol Hepatol; 2002 Jul; 14(7):771-4. PubMed ID: 12169987
[TBL] [Abstract][Full Text] [Related]
2. Impact of SEN virus on immunoblot INNO-LIA HCV reactivity pattern and disease outcome in Egyptian hepatocellular carcinoma patients.
Alam El-Din HM; Abo-Shadi MA; Helal A
Egypt J Immunol; 2007; 14(1):1-10. PubMed ID: 18689276
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Watanabe N
Autoimmunity; 2005 Sep; 38(6):445-8. PubMed ID: 16278150
[TBL] [Abstract][Full Text] [Related]
4. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.
Imai H; Nakano Y; Kiyosawa K; Tan EM
Cancer; 1993 Jan; 71(1):26-35. PubMed ID: 8380118
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody responses in Chinese hepatocellular carcinoma.
Zhang JY; Wang X; Peng XX; Chan EK
J Clin Immunol; 2002 Mar; 22(2):98-105. PubMed ID: 11998899
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus and HIV antibodies in patients with hepatocellular carcinoma in Zimbabwe: a pilot study.
Weinig M; Hakim JG; Gudza I; Tobaiwa O
Trans R Soc Trop Med Hyg; 1997; 91(5):570-2. PubMed ID: 9463670
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma.
Nomura F; Sogawa K; Noda K; Seimiya M; Matsushita K; Miura T; Tomonaga T; Yoshitomi H; Imazeki F; Takizawa H; Mogushi K; Miyazaki M; Yokosuka O
Biochem Biophys Res Commun; 2012 May; 421(4):837-43. PubMed ID: 22554520
[TBL] [Abstract][Full Text] [Related]
8. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis.
Le Naour F; Brichory F; Misek DE; Bréchot C; Hanash SM; Beretta L
Mol Cell Proteomics; 2002 Mar; 1(3):197-203. PubMed ID: 12096119
[TBL] [Abstract][Full Text] [Related]
9. [Progressive increase of serum circulating immune complexes and its significance in patients during the progression from chronic hepatitis B to hepatocellular carcinoma].
Du J; Tian P; Chen TY; Wu JX; Wang JB; Wei Y; Wang LM; Liu LG; Ji WS; Qu CF
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):905-10. PubMed ID: 22340099
[TBL] [Abstract][Full Text] [Related]
10. Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C.
Ezzikouri S; Kimura K; Sunagozaka H; Kaneko S; Inoue K; Nishimura T; Hishima T; Kohara M; Tsukiyama-Kohara K
EBioMedicine; 2015 Jun; 2(6):604-12. PubMed ID: 26288822
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan.
Marusawa H; Osaki Y; Kimura T; Ito K; Yamashita Y; Eguchi T; Kudo M; Yamamoto Y; Kojima H; Seno H; Moriyasu F; Chiba T
Gut; 1999 Aug; 45(2):284-8. PubMed ID: 10403743
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma.
Wang K; Chen Y; Liu S; Qiu S; Gao S; Huang X; Zhang J; Peng X; Qiani W; Zhang JY
Int J Immunopathol Pharmacol; 2009; 22(3):735-43. PubMed ID: 19822090
[TBL] [Abstract][Full Text] [Related]
13. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
14. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma.
Hann HW; Lee J; Bussard A; Liu C; Jin YR; Guha K; Clayton MM; Ardlie K; Pellini MJ; Feitelson MA
Cancer Res; 2004 Oct; 64(20):7329-35. PubMed ID: 15492253
[TBL] [Abstract][Full Text] [Related]
15. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients.
Hassan MM; Zaghloul AS; El-Serag HB; Soliman O; Patt YZ; Chappell CL; Beasley RP; Hwang LY
J Clin Gastroenterol; 2001 Aug; 33(2):123-6. PubMed ID: 11468438
[TBL] [Abstract][Full Text] [Related]
16. HBV + HCV = HCC?
Cramp ME
Gut; 1999 Aug; 45(2):168-9. PubMed ID: 10403725
[No Abstract] [Full Text] [Related]
17. Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma.
Ying X; Han SX; He CC; Zhou CY; Dong YP; Cai MJ; Sui X; Ma CX; Sun X; Zhang YY; Gou WL; Mason C; Zhu Q
Oncotarget; 2017 Apr; 8(15):24828-24839. PubMed ID: 28186997
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma.
Motta M; Pistone G; Franzone AM; Romeo MA; Di Mauro S; Giugno I; Ruello P; Malaguarnera M
Panminerva Med; 2003 Mar; 45(1):69-73. PubMed ID: 12682623
[TBL] [Abstract][Full Text] [Related]
19. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.
Ying X; Zhao Y; Wang JL; Zhou X; Zhao J; He CC; Guo XJ; Jin GH; Wang LJ; Zhu Q; Han SX
Oncol Rep; 2014 Oct; 32(4):1550-6. PubMed ID: 25109745
[TBL] [Abstract][Full Text] [Related]
20. Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma.
Liu M; Varela-Ramirez A; Li J; Dai L; Aguilera RJ; Zhang JY
Oncol Rep; 2015 May; 33(5):2245-52. PubMed ID: 25779011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
